Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Argenx in the Spotlight

Watch our new series of executive interviews featuring leaders from our portfolio companies. In this episode, we spotlight Karen Massey, Chief Operating Officer at Argenx.

In conversation with our Deputy Head of Investment Management, Maurizio Bernasconi, Ms. Massey discusses the patients’ burden in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), highlights the recent positive phase 3 results of efgartigimod in this indication, and outlines the launch strategy a few weeks ahead of its potential approval by the US FDA.
21.05.2024 - Maurizio Bernasconi
Argenx in the Spotlight

This might also interest you

  • BB Biotech AG

    BB Biotech AG (SIX) (CHF)
    ISIN-No.: CH0038389992YTD: 23.47%Active share: 79.47Anzahl Positionen: 22
    Launch date: 16. November 1993